Use of Contrast-Enhanced Ultrasound with Sonazoid for Evaluating the Radiotherapy Efficacy for Hepatocellular Carcinoma

Akihiro Funaoka(Yokohama City University Medical Center), Shin Maeda(University of Tokyo Hospital), Kazushi Numata(Yokohama City University Medical Center), Yusuke Saigusa(Yokohama City University), Masahiro Okada, Hiromi Nihonmatsu(Yokohama City University Medical Center), Hiroyuki Fukuda(Yokohama City University Medical Center), Yuichiro Tsurugai(Gunma Chuo Hospital), Atsuya Takeda(Gunma Chuo Hospital), Masayuki Nakano(Nihon University), Makoto Chuma(Yokohama City University Medical Center)
Diagnostics
March 9, 2021
10.3390/diagnostics11030486
Cited by 8

Related Papers

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2023|514
Imaging Study of Early Hepatocellular Carcinoma: Usefulness of Gadoxetic Acid–enhanced MR Imaging
|Radiology|2011|354
cHCC‐CCA
|Hepatology|2018|333
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)
|Hepatology Research|2023|281